Use of chiral liquid chromatography for the evaluation of stereospecificity in the carbonyl reduction of potential benzo[c]fluorene antineoplastics benfluron and dimefluron in various species

Journal of Pharmaceutical and Biomedical Analysis

Volumn 37, Issue 5, 2005, Pages 1049-1057

  Kucera R ^a   Nobilis, M ^a,b   Skalova L ^a   Szotakova B ^a   Cisar P ^a   Jira, Th ^c   Klimes J ^a   Wsol V ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b INSTITUTE OF MATHEMATICS   (Czech Republic)

^c UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Benfluron and dimefluron; Carbonyl reduction metabolites; Chiral HPLC; Potential antineoplastics

Indexed keywords

3,9 DIMETHOXY 5 (2 DIMETHYLAMINOETHOXY) 7H BENZO[C]FLUOREN 7 ONE; ACETONITRILE; ANTINEOPLASTIC AGENT; BENFLURON; CARBONYL DERIVATIVE; METHANOL; UNCLASSIFIED DRUG;

ADULT; ANALYTIC METHOD; ANIMAL TISSUE; CHIRAL CHROMATOGRAPHY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DETERMINATION; DRUG TRANSFORMATION; ENANTIOMER; EVALUATION; FLOW RATE; GOAT; GUINEA PIG; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; REDUCTION; SPECIES DIFFERENCE; STEREOSPECIFICITY; SWINE;

EID: 18144427416     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2004.10.005     Document Type: Conference Paper

References (30)

1. B. Testa, and J. Caldwell Biochemistry of Redox Reactions 1995 Academic Press London
2. R. Felsted, and N.R. Bachur Drug Metab. Rev. 11 1980 1 60
3. B. Wermuth Prog. Clin. Biol. Res. 174 1985 209 230
4. J.J.R. Hermans, and H.H.W. Thijssen Adv. Exp. Med. Biol. 328 1993 351 360
5. E. Masser Biochem. Pharmacol. 49 1995 421 440
6. M. Miko, J. Křepelka, and M. Mělka Biochem. Pharmacol. 42 1991 214 216
7. E. Kvasničková, M. Nobilis, and I.M. Hais J. Chromatogr. 295 1984 201 209
8. E. Kvasničková, M. Nobilis, A. Šroler, E. Báčová, and I.M. Hais J. Chromatogr. 387 1987 559 561
9. I.M. Hais, M. Nobilis, and E. Kvasničková J. Chromatogr. 500 1990 643 653
10. E. Kvasničková, I.M. Hais, and M. Nobilis P. Hlavica Progress in Pharmacology and Clinical Pharmacology 1991 Gustav Fischer Verlag Stuttgart, NY 137 146
11. M. Miko, J. Křepelka, and M. Nobilis D. Adam Recent Advances in Chemotherapy 1992 Futuramed Publishers Munich 2620 2621
12. M. Nobilis, E. Kvasničková, A. Šroler, and I.M. Hais Drug Metab. Drug Interact. 9 1991 225 240
13. E. Kvasničková, M. Nobilis, A. Šroler, V. Wsól, and I.M. Hais D. Crommelin P. Couvreur D. Duchéne In vitro and Ex vivo Test Systems to Rationalize Drug Design and Delivery 1994 Editions de Santé Paris 331 335
14. M. Nobilis, P. Anzenbacher, J. Pastera, Z. Svoboda, K. Hrubý, J. Květina, K. Ubik, and F. Trejtnar J. Chromatogr. B 681 1996 143 151
15. L. Skálová, M. Nobilis, B. Szotáková, F. Trejtnar, and E. Kvasničková Exp. Toxicol. Pathol. 48 Suppl. II 1996 366 370
16. K. Hrubý, E. Anzenbacherová, P. Anzenbacher, and M. Nobilis Gen. Physiol. Biophys. 16 1997 321 327
17. L. Skálová, M. Nobilis, B. Szotáková, V. Wsól, and E. Kvasničková Drug Metabol. Drug Interact. 14 1998 221 234
18. L. Skálová, M. Nobilis, B. Szotáková, V. Wsól, and E. Kvasničková Drug Metabol. Drug Interact. 14 1998 235 250
19. Z. Svoboda, M. Nobilis, J. Květina, and K. Lemr Acta Med. (Hradec Králové) 42 1999 73 78
20. L. Skálová, M. Nobilis, B. Szotáková, V. Wsól, Vl. Kubíček, V. Baliharová, and E. Kvasničková Chem. -Biol. Interact. 126 2000 185 200
21. K. Hrubý, E. Anzenbacherová, P. Anzenbacher, and M. Nobilis Collect. Czech. Chem. Cornmun. 65 2000 1374 1386
22. M. Nobilis, L. Skálová, B. Szotáková, J. Kujíček, M. Pour, J. Kuneš, M. Mělka, E. Kvasničková, and Vl. Geršl Drug Metab. Rev. 33 Suppl. 1 2001 116
23. L. Skálová, M. Nobilis, B. Szotáková, E. Kondrová, M. Šavlík, V. Wsól, L.P. Garcia, and E. Maser Biochem. Pharmacol. 64 2002 297 305
24. P. Císař, M. Nobilis, J.Klimeš, in: Abstract Book of the 32nd conference Synthesis and Analysis of Drugs (ISBN 80-900306-5-3), p. 19.
25. S. Janotová, and K. Horáková Cell Biochem. Funct. 11 1993 131 135
26. M. Miko, J. Křepelka, and M. Mělka Anti-cancer Drugs 2 1991 289 295
27. M. Miko, J. Křepelka, and M. Nobilis Anti-cancer Drugs 3 1992 63 68
28. P.K. Smith, R.I. Krohn, G.T. Hermanson, A.K. Mallia, F.H. Gartner, M.D. Provenzano, E.K. Fujimoto, N.M. Goeke, B.J. Olson, and D.C. Klenk Anal. Biochem. 150 1985 76 85
29. V.P. Shah, K.K. Midha, and S.V. Dighe Int. J. Pharm. 82 1992 1 7
30. CDER and CVM Guidance for Industry. Bioanalytical Method Validation, May 2001 (http://www.fda.gov/cder/guidance/).